UNIGE document Scientific Article
previous document  unige:26051  next document
add to browser collection
Title

Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab

Authors
Miederer, M
Vranjes-Durić, S
Comor, J J
Senekowitsch-Schmidtke, R
Soloviev, D
show hidden authors show all authors [1 - 9]
Published in European Journal of Nuclear Medicine and Molecular Imaging. 2004, vol. 31, no. 4, p. 547-54
Abstract This study demonstrates high-efficiency sterilisation of single cancer cells in a SCID mouse model of leukaemia using rituximab, a monoclonal antibody that targets CD20, labelled with terbium-149, an alpha-emitting radionuclide. Radio-immunotherapy with 5.5 MBq labelled antibody conjugate (1.11 GBq/mg) 2 days after an intravenous graft of 5.10(6) Daudi cells resulted in tumour-free survival for >120 days in 89% of treated animals. In contrast, all control mice (no treatment or treated with 5 or 300 micro g unlabelled rituximab) developed lymphoma disease. At the end of the study period, 28.4%+/-4% of the long-lived daughter activity remained in the body, of which 91.1% was located in bone tissue and 6.3% in the liver. A relatively high daughter radioactivity concentration was found in the spleen (12%+/-2%/g), suggesting that the killed cancer cells are mainly eliminated through the spleen. This promising preliminary in vivo study suggests that targeted alpha therapy with (149)Tb is worthy of consideration as a new-generation radio-immunotherapeutic approach.
Keywords Alpha Particles/therapeutic useAnimalsAntibodiesMonoclonal/pharmacokinetics/therapeutic useAntibodiesMonoclonalMurine-DerivedAntineoplastic Agents/therapeutic useApoptosis/radiation effectsCell LineTumorCell Survival/radiation effectsDose-Response RelationshipDrugDrug Delivery Systems/methodsEvidence-Based Medicine/methodsFemaleLeukemia/drug therapy/metabolism/radiotherapyMiceMiceSCIDOrgan SpecificityRadioimmunotherapy/methodsRadiopharmaceuticals/therapeutic useReproducibility of ResultsSurvivalTissue DistributionTreatment Outcome
Identifiers
PMID: 14722680
Full text
Article (Published version) (329 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group HIV (835)
Citation
(ISO format)
BEYER, Gerd-Jurgen et al. Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab. In: European Journal of Nuclear Medicine and Molecular Imaging, 2004, vol. 31, n° 4, p. 547-54. https://archive-ouverte.unige.ch/unige:26051

193 hits

0 download

Update

Deposited on : 2013-01-30

Export document
Format :
Citation style :